Oregon Public Employees Retirement Fund increased its stake in Eli Lilly and Co. (NYSE:LLY) by 2.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 211,177 shares of the company’s stock after buying an additional 5,509 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Eli Lilly and were worth $16,949,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Cullinan Associates Inc. increased its position in shares of Eli Lilly and by 0.9% in the first quarter. Cullinan Associates Inc. now owns 32,367 shares of the company’s stock valued at $2,331,000 after buying an additional 300 shares during the period. BlueMountain Capital Management LLC bought a new position in shares of Eli Lilly and during the first quarter valued at about $482,000. Iowa State Bank bought a new position in shares of Eli Lilly and during the second quarter valued at about $104,000. Stock Yards Bank & Trust Co. increased its position in shares of Eli Lilly and by 11.0% in the second quarter. Stock Yards Bank & Trust Co. now owns 22,976 shares of the company’s stock valued at $1,810,000 after buying an additional 2,283 shares during the period. Finally, New England Research & Management Inc. bought a new position in shares of Eli Lilly and during the second quarter valued at about $583,000. Institutional investors and hedge funds own 75.11% of the company’s stock.
Eli Lilly and Co. (NYSE:LLY) traded up 1.65% during midday trading on Friday, hitting $69.12. The stock had a trading volume of 8,620,682 shares. Eli Lilly and Co. has a 1-year low of $64.18 and a 1-year high of $88.16. The stock’s 50-day moving average is $76.69 and its 200-day moving average is $77.92. The stock has a market capitalization of $73.11 billion, a PE ratio of 30.07 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. The company earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. Eli Lilly and’s revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.89 earnings per share. On average, equities research analysts anticipate that Eli Lilly and Co. will post $3.55 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date is Thursday, November 10th. Eli Lilly and’s dividend payout ratio is currently 88.70%.
Several analysts have weighed in on the company. Citigroup Inc. reissued a “buy” rating on shares of Eli Lilly and in a report on Wednesday, August 3rd. Argus boosted their price objective on Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a report on Friday, July 29th. Leerink Swann reissued a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a report on Sunday, October 9th. Finally, BMO Capital Markets reissued a “buy” rating and set a $94.00 price objective on shares of Eli Lilly and in a report on Monday, October 3rd. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $108.95.
In related news, insider Maria A. Crowe sold 2,248 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the transaction, the insider now directly owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.20% of the stock is owned by corporate insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.